The estimated Net Worth of Ann Lucena is at least $148 Thousand dollars as of 22 August 2023. Ann Lucena owns over 7,500 units of Cerus stock worth over $148,182 and over the last 3 years Ann sold CERS stock worth over $0.
Ann has made over 1 trades of the Cerus stock since 2023, according to the Form 4 filled with the SEC. Most recently Ann bought 7,500 units of CERS stock worth $12,675 on 22 August 2023.
The largest trade Ann's ever made was buying 7,500 units of Cerus stock on 22 August 2023 worth over $12,675. On average, Ann trades about 1,875 units every 0 days since 2021. As of 22 August 2023 Ann still owns at least 72,284 units of Cerus stock.
You can see the complete history of Ann Lucena stock trades at the bottom of the page.
Ann's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD, CA, 94520.
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash, and Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: